| PAR2 activation on human tubular epithelial cells engages converging signaling pathways to induce an inflammatory and fibrotic milieu DA Vesey, A Iyer, E Owen, D Kamato, DW Johnson, GC Gobe, DP Fairlie, ... Frontiers in Pharmacology 15, 1382094, 2024 | | 2024 |
| Moscatilin inhibits vascular calcification by activating IL13RA2-dependent inhibition of STAT3 and attenuating the WNT3/β-catenin signalling pathway T Zhang, M Zhu, J Ma, Z Liu, Z Zhang, M Chen, Y Zhao, H Li, S Wang, ... Journal of Advanced Research, 2024 | | 2024 |
| Transforming growth factor-β receptors: versatile mechanisms of ligand activation ZJ Chia, Y Cao, PJ Little, D Kamato Acta Pharmacologica Sinica, 1-12, 2024 | 1 | 2024 |
| Lipid: Extracellular Matrix Interactions as Therapeutic Targets in the Atherosclerosis of Diabetes D Kamato, PJ Little Lipoproteins in Diabetes Mellitus, 319-336, 2023 | | 2023 |
| Mechanistic insight: linking cardiovascular complications of inflammatory bowel disease H Kumarapperuma, R Wang, PJ Little, D Kamato Trends in Cardiovascular Medicine, 2023 | 7 | 2023 |
| Gαq is the specific mediator of PAR-1 transactivation of kinase receptors in vascular smooth muscle cells D Kamato, M Gabr, H Kumarapperuma, ZJ Chia, W Zheng, S Xu, ... International Journal of Molecular Sciences 23 (22), 14425, 2022 | 1 | 2022 |
| Mouse models of atherosclerosis in translational research I Ilyas, PJ Little, Z Liu, Y Xu, D Kamato, BC Berk, J Weng, S Xu Trends in Pharmacological Sciences 43 (11), 920-939, 2022 | 37 | 2022 |
| Non-mouse models of atherosclerosis: approaches to exploring the translational potential of new therapies D Kamato, I Ilyas, S Xu, PJ Little International Journal of Molecular Sciences 23 (21), 12964, 2022 | 5 | 2022 |
| Endothelin‐1 dependent expression of GAG genes involves NOX and p38 mediated Smad linker region phosphorylation H Babaahmadi‐Rezaei, R Mohamed, P Dayati, RN Mehr, F Seif, ... Clinical and Experimental Pharmacology and Physiology 49 (7), 710-718, 2022 | 2 | 2022 |
| Akt acts as a switch for GPCR transactivation of the TGF‐β receptor type 1 R Mohamed, A Shajimoon, R Afroz, M Gabr, WG Thomas, PJ Little, ... The FEBS Journal 289 (9), 2642-2656, 2022 | 7 | 2022 |
| Endothelin-1 mediated glycosaminoglycan synthesizing gene expression involves NOX-dependent transactivation of the transforming growth factor-β receptor H Babaahmadi-Rezaei, PJ Little, R Mohamed, GM Zadeh, A Kheirollah, ... Molecular and Cellular Biochemistry 477 (4), 981-988, 2022 | 11 | 2022 |
| Influence of PEGylated porous silicon nanoparticles on permeation and efflux of an orally administered antibiotic A Raza, D Kamato, FB Sime, JA Roberts, A Popat, JR Falconer, ... Materials Today Advances 13, 100210, 2022 | 10 | 2022 |
| YY‐11, a camel milk‐derived peptide, inhibits TGF‐β‐mediated atherogenic signaling in human vascular smooth muscle cells H Hussain, Y Cao, R Mohamad, R Afroz, Y Zhou, P Moyle, N Bansal, ... Journal of Food Biochemistry 46 (3), e13882, 2022 | 1 | 2022 |
| Lipopolysaccharide acting via toll-like receptor 4 transactivates the TGF-β receptor in vascular smooth muscle cells R Afroz, H Kumarapperuma, QVN Nguyen, R Mohamed, PJ Little, ... Cellular and Molecular Life Sciences 79 (2), 121, 2022 | 7 | 2022 |
| Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies S Xu, I Ilyas, PJ Little, H Li, D Kamato, X Zheng, S Luo, Z Li, P Liu, J Han, ... Pharmacological reviews 73 (3), 924-967, 2021 | 554 | 2021 |
| Endothelial dysfunction and cardiovascular disease: History and analysis of the clinical utility of the relationship PJ Little, CD Askew, S Xu, D Kamato Biomedicines 9 (6), 699, 2021 | 49 | 2021 |
| Curcumin inhibits lysophosphatidic acid mediated MCP-1 expression via blocking ROCK signalling Y Zhou, PJ Little, S Xu, D Kamato Molecules 26 (8), 2320, 2021 | 16 | 2021 |
| Targeted molecular imaging of cardiovascular diseases by iron oxide nanoparticles KX Vazquez-Prada, J Lam, D Kamato, ZP Xu, PJ Little, HT Ta Arteriosclerosis, Thrombosis, and Vascular Biology 41 (2), 601-613, 2021 | 61 | 2021 |
| Endothelial Dysfunction and Cardiovascular Disease: History and Analysis of the Clinical Utility of the Relationship. Biomedicines 2021, 9, 699 PJ Little, CD Askew, S Xu, D Kamato s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2021 | | 2021 |
| Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics Z Liu, X Ma, I Ilyas, X Zheng, S Luo, PJ Little, D Kamato, A Sahebkar, ... Theranostics 11 (9), 4502, 2021 | 89 | 2021 |
Prof. Peter J. Little AMSchool of Pharmacy, The University of Queensland在 uq.edu.au 的电子邮件经过验证
